S'abonner

Myricetin ameliorates cognitive impairment in 3×Tg Alzheimer’s disease mice by regulating oxidative stress and tau hyperphosphorylation - 23/07/24

Doi : 10.1016/j.biopha.2024.116963 
Li Wang a, 1, Zhi Tang a, 1, Bo Li a, Yaqian Peng a, Xi Yang b, Yan Xiao a, Ruiqing Ni c, d, , Xiao-lan Qi a, e,
a Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education and Key Laboratory of Medical Molecular Biology of Guizhou Province, Key Laboratory of Molecular Biology of Guizhou Medical University, Guiyang, China 
b Guiyang Healthcare Vocational University, Guizhou ERC for Medical Resources & Healthcare Products (Guizhou Engineering Research Center for Medical Resources and Healthcare Products), Guiyang, Guizhou, China 
c Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland 
d Institute for Biomedical Engineering, ETH Zurich & University of Zurich, Zurich, Switzerland 
e Collaborative Innovation Center for Prevention and Control of Endemic and Ethnic Regional Diseases Constructed by the Province and Ministry, Guiyang, China 

Correspondence to: Wagistrasse 12, 9th floor, Zurich 8952, Switzerland.Wagistrasse 12, 9th floorZurich8952Switzerland⁎⁎Correspondence to: Beijing Road No.9, Guiyang 550001, China.Beijing Road No.9Guiyang550001China

Abstract

Background

Alzheimer's disease is characterized by abnormal β-amyloid (Aβ) plaque accumulation, tau hyperphosphorylation, reactive oxidative stress, mitochondrial dysfunction and synaptic loss. Myricetin, a dietary flavonoid, has been shown to exert neuroprotective effects in vitro and in vivo. Here, we aimed to elucidate the mechanism and pathways involved in the protective effect of myricetin.

Methods

The effect of myricetin was assessed on Aβ42 oligomer-treated neuronal SH-SY5Y cells and in 3×Tg mice. Behavioral tests were performed to assess the cognitive effects of myricetin (14 days, ip) in 3×Tg mice. The levels of beta-amyloid precursor protein (APP), synaptic and mitochondrial proteins, glycogen synthase kinase3β (GSK3β) and extracellular regulated kinase (ERK) 2 were assessed via Western blotting. Flow cytometry assays, immunofluorescence staining, and transmission electron microscopy were used to assess mitochondrial dysfunction and reactive oxidative stress.

Results

We found that, compared with control treatment, myricetin treatment improved spatial cognition and learning and memory in 3×Tg mice. Myricetin ameliorated tau phosphorylation and the reduction in pre- and postsynaptic proteins in Aβ42 oligomer-treated neuronal SH-SY5Y cells and in 3×Tg mice. In addition, myricetin reduced reactive oxygen species generation, lipid peroxidation, and DNA oxidation, and rescued mitochondrial dysfunction via the associated GSK3β and ERK 2 signalling pathways.

Conclusions

This study provides new insight into the neuroprotective mechanism of myricetin in vitro in cell culture and in vivo in a mouse model of Alzheimer’s disease.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




 : 

This study provides new insight into the cognitive improving mechanism of myricetin by ameliorating tau phosphorylation and restoring pre/postsynaptic proteins. Myricetin could reduce reactive oxygen species generation, lipid peroxidation, and DNA oxidation. and rescue mitochondrial dysfunction via the associated GSK3β and ERK signalling pathways.


This study provides new insight into the cognitive improving mechanism of myricetin by ameliorating tau phosphorylation and restoring pre/postsynaptic proteins. Myricetin could reduce reactive oxygen species generation, lipid peroxidation, and DNA oxidation. and rescue mitochondrial dysfunction via the associated GSK3β and ERK signalling pathways.

Le texte complet de cet article est disponible en PDF.

Highlights

Myricetin prevented Aβ42O-induced tau hyperphosphorylation.
Myricetin ameliorated Aβ42O-induced synaptic impairment.
Myricetin alleviated the phosphorylation of ERK2 and GSK3β.
Myricetin restored mitochondrial fission protein and membrane potential reduction.
Myricetin blocked ROS production, lipid peroxidation, and DNA oxidation.

Le texte complet de cet article est disponible en PDF.

Keywords : Alzheimer’s disease, Myricetin, Tau, Oxidative stress, Synaptic impairment


Plan


© 2024  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 177

Article 116963- août 2024 Retour au numéro
Article précédent Article précédent
  • Combined targeted therapy with PI3K and CDK4/6, or FGFR inhibitors show synergistic effects in a neuroblastoma spheroid culture model
  • Monika Lukoseviciute, Emma Need, Stefan Holzhauser, Tina Dalianis, Ourania N. Kostopoulou
| Article suivant Article suivant
  • Isorhamnetin improves diabetes-induced erectile dysfunction in rats through activation of the PI3K/AKT/eNOS signaling pathway
  • Yinhui Mao, Yarong Zha, Yueyue Zang, Yanan Gao, Juntao Sun, Yang Liu, Zhuo Wang, Zhitao Wei, Mingxing Wang, Yong Yang

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.